Refoxy Pharma is a technology company.
Refoxy Pharma has raised $10.0M across 1 funding round.
Refoxy Pharma has raised $10.0M in total across 1 funding round.
Refoxy Pharma has raised $10.0M in total across 1 funding round.
Refoxy Pharma's investors include Coparion.
Refoxy Pharma is a biotechnology company specializing in developing novel therapeutics by activating FOXO3, a key transcription factor involved in biological homeostasis and aging. Their proprietary discovery platform, F.act finder (FOXO activator finder), identifies molecules that specifically modulate FOXO3 to treat fibrotic disorders, with an initial focus on idiopathic pulmonary fibrosis (IPF), a severe lung disease with limited treatment options. Refoxy aims to address aging-associated diseases by leveraging FOXO3’s role in stress resistance and tissue repair, serving patients with chronic fibrotic and age-related conditions. The company has demonstrated growth momentum through successful fundraising rounds, including a €9.1 million raise to advance its pipeline[1][2][3].
Founded in 2020 in Germany, Refoxy Pharma was co-founded by Dr. Victor Bustos and Professor Wolfgang Link, a world-renowned expert in FOXO3 biology. The idea emerged from pioneering research on FOXO3’s potential to regulate longevity and tissue homeostasis. Their collaboration, supported by Apollo Health Ventures, led to the creation of the F.act finder platform to discover FOXO3 activators. Early traction includes building a focused pipeline targeting fibrotic diseases, particularly IPF, and securing significant investment to progress preclinical development[2][3].
Refoxy Pharma rides the growing trend of longevity and age-related disease therapeutics, a field gaining momentum due to demographic shifts and increasing demand for treatments that extend healthy lifespan. The timing is critical as advances in molecular biology and drug discovery enable targeting complex aging pathways like FOXO3. Market forces such as rising prevalence of chronic fibrotic diseases and aging populations favor innovation in this space. Refoxy’s approach influences the biotech ecosystem by pioneering FOXO3 activation as a therapeutic strategy, potentially opening new avenues for age-related disease intervention[2][3].
Looking ahead, Refoxy Pharma is poised to advance its FOXO3 activator pipeline through preclinical and clinical stages, potentially expanding indications beyond IPF to other fibrotic and aging-associated diseases. Trends in precision medicine, aging research, and regenerative therapies will shape their journey. Their influence may grow as FOXO3 modulation proves clinically effective, positioning Refoxy as a leader in longevity biotech. Continued investment and scientific validation will be key to realizing their vision of novel therapies that enhance healthspan by harnessing the body’s natural defense mechanisms[2][3][5].
Refoxy Pharma has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $10.0M Seed | Coparion |